EGFR+ Lung Cancer | Clinical

Therapies on the Horizon in EGFR Exon 20–Positive Lung Cancer

January 15, 2021

In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.

Early-Phase Trial Data of EGFR Inhibitors Lead to Successful Use of Osimertinib in Resected EGFR+ NSCLC

January 10, 2021

Osimertinib has been a successful therapy for the treatment of EGFR-positive non–small cell lung cancer, surpassing the effects of chemotherapy. In he adjuvant setting, physicians questions when and how to use osimertinib.

Phase 3 ADAURA Study Highlights Role for Precision Medicine in EGFR-Positive NSCLC

January 05, 2021

Masahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.

Positive Findings From ADAURA Trial Reported, But Questions Remain

December 29, 2020

The early unblinding of results from the phase 3 ADAURA clinical trial evaluating osimertinib, a third-generation EGFR tyrosine kinase inhibitor, was met with much fanfare in the oncology community as details of the interim results spread.

Frontline Regimens Explored for EGFR-Mutated NSCLC

December 20, 2020

During a Targeted Oncology Case Based Peer Perspective event, John Heymach, MD, PhD Chair, Department of Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center, discusses the case of a 73-year-old Asian patients with EGFR-mutant non–small cell lung cancer.

FDA Approves Osimertinib as Adjuvant Therapy for EGFR+ NSCLC

December 18, 2020

The FDA has approved osimertinib as an adjuvant therapy for patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test, for use following tumor resection.

New Evidence Supports Targeted Therapies in Early-Stage NSCLC With EGFR Mutations

December 16, 2020

During a Targeted Oncology Case Based Peer Perspectives event Karen L. Kelly, MD, discussed molecular testing guidelines and testing execution for early-stage non–small cell lung cancer as well as the research supporting the use of targeted therapies for treatment.

Trials Demonstrate Which Treatments Physicians Should Use in EGFR+ NSCLC

December 14, 2020

Edgardo S. Santos Castillero, MD, reviewed the case of a 73-year-old Asian man who was diagnosed with stage IV EGFR-mutant non-small cell lung cancer and discussed the treatment options he would consider for this patient.

Phase 3 LAURA Study to Explore Efficacy of Maintenance Osimertinib in Stage III EGFR-Mutant NSCLC

December 14, 2020

The phase 3 LAURA clinical trial is currently enrolling patients with stage III, unresectable EGFR-mutant non–small cell lung cancer to explore the efficacy and safety of the third-generation tyrosine kinase inhibitor osimertinib as maintenance therapy following chemoradiation.

Osimertinib Plays a Role for Patients With EGFR-Mutant NSCLC

December 04, 2020

Masahiro Tsuboi, MD, discusses treatment with osimertinib for patients with EGFR-mutated non–small cell lung cancer and central nervous system disease recurrence.